Long-term experiences on cardiac retransplantation in adults

Eur J Cardiothorac Surg. 2007 Dec;32(6):923-5. doi: 10.1016/j.ejcts.2007.08.031. Epub 2007 Oct 29.

Abstract

Background: It remains disputed whether cardiac retransplantation should be performed. This study aimed to evaluate our long-term experiences on cardiac retransplantation in adults.

Patients and methods: Between March 1989 and December 2004, 2% (28/1290) of cardiac retransplantations were performed.

Results: The reasons for cardiac retransplantation were cardiac allograft vasculopathy (n=13; 47%), primary graft failure (n=11; 39%), and refractory acute rejection (n=4; 14%). The 30-day mortality risk was 29% (acute rejection: 50%; primary graft failure: 36%; cardiac allograft vasculopathy: 15%, p=0.324), compared to 8.5% for primary cardiac transplantation (p<0.001). The causes of early death were acute rejection (n=3; 37%), multiorgan failure (n=3; 37%), primary graft failure (n=1; 13%), and right ventricular failure (n=1; 13%). The late mortality rate was 96/1000 patient-years. The causes of late death were acute rejection (n=4; 50%), cardiac allograft vasculopathy (n=2; 25%), multiorgan failure (n=1; 13%), and infection (n=1; 13%). The 1-, 5-, 10-, and 15-year survival was respectively 78, 68, 54, and 38% (primary cardiac transplantation), and 46, 41, 32, and 32% (cardiac retransplantation) (p=0.003). The short-term survival for cardiac retransplantation due to cardiac allograft vasculopathy was likely better than primary graft failure and refractory acute rejection (p=0.09).

Conclusion: The overall outcomes of cardiac retransplantation are significantly inferior to primary cardiac transplantation. Cardiac retransplantation should be only performed for selected patients.

Publication types

  • Evaluation Study

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Female
  • Graft Rejection / surgery
  • Heart Failure / surgery
  • Heart Transplantation*
  • Heart-Assist Devices
  • Humans
  • Male
  • Middle Aged
  • Postoperative Period
  • Prognosis
  • Reoperation
  • Survival Analysis
  • Tissue Donors
  • Treatment Outcome